中文

万邦医药 Revenue Breakdown

Period 2026-03-31 ・ Reported 2026-04-23
ItemAmountY/Y
Revenue¥0.03B-57.0%
Gross profit¥0.00B
Operating income¥-0.00B
Net income¥-0.00B-102.2%
Gross margin15.2%Net margin -0.9%
Revenue Q/Q-52.8%

Revenue Segments

The filing did not disclose a revenue breakdown for this period.

Costs & Expenses

ItemAmount% of revenue
Cost of revenue¥0.03B84.8%
R&D¥0.01B26.4%
SG&A¥0.01B21.2%
Tax & other¥-0.00B-5.1%
Generate the full Sankey chart →

The Sankey chart shows how revenue splits into cost of revenue, R&D and SG&A, and what remains as profit — clean visuals for research decks and social posts.

Other companies

上大股份儒竞科技国际复材多浦乐福赛科技春光集团威马农机浙江华远星宸科技骏鼎达宏鑫科技崇德科技

Source: Eastmoney · This page shows public filing data only, not investment advice. · Browse all companies